A Phase 1 Open-label, Dose-escalation, Safety, and Tolerability Study of JSP191 As a Second-line Therapy in Subjects with Lower-Risk Myelodysplastic Syndrome (LR-MDS)
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Sponsor
- Jasper Therapeutics, Inc.
- Enrollment
- 6
- Locations
- 2
- Primary Endpoint
- Safety and tolerability of JSP191
Study Overview
Brief Summary
A Phase 1 study in subjects with LR-MDS to assess the safety and tolerability of JSP191 as a second-line therapy.
Detailed Description
An open-label, single-arm, dose-escalation study designed to determine the potential safety, efficacy, maximum tolerated dose (MTD) or optimal biologic dose (OBD), and recommended phase 2 dose (RP2D) of JSP191 (briquilimab) monotherapy for LR-MDS subjects with documented cytopenia (red blood cell-transfusion dependent, thrombocytopenia, and/or neutropenia).
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Sequential
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age ≥ 18 years
- •MDS with IPSS-R very low, low, or intermediate risk features
- •Symptomatic cytopenias
- •Women of childbearing potential (WOCBP) must agree to use an oral or implanted contraceptive, a double-barrier method of birth control, or an intrauterine device upon enrollment and through 3 months after receiving the last dose of JSP191
- •Women not of childbearing potential must be post-menopausal (no menstrual period for a minimum of 12 months) or surgically sterilized and have a negative serum pregnancy test upon study entry
- •Male subjects must be surgically sterile or willing to use contraception upon enrollment and through 3 months after receiving the last dose of JSP191
- •Must be willing and able to provide informed consent
Exclusion Criteria
- •Anemia secondary to iron deficiency, vitamin B12 deficiency, or folate deficiency
- •Prior allogeneic or autologous stem cell transplant
- •Known history of human immunodeficiency virus (HIV) (no laboratory testing is required), or active infection with hepatitis B or hepatitis C
- •Pregnant women or women who are nursing and do not wish to discontinue breastfeeding
- •Any other medical condition that, in the opinion of the Investigator, could pose a significant safety risk to the subject or jeopardize the integrity of the study
- •Subjects who, in the opinion of the Investigator, may not be able to comply with the requirements of the study
Arms & Interventions
JSP191
This study will explore up to 5 ascending dose levels (Cohorts 1, 2, 3, 4, and 5) and subjects will receive JSP191 on Day 1 on each 8-week cycle for 4 consecutive cycles.
Intervention: JSP191 (Drug)
Outcomes
Primary Outcomes
Safety and tolerability of JSP191
Time Frame: 32 weeks
Assessed by the frequency, duration, and severity of adverse events
Secondary Outcomes
No secondary outcomes reported